Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Date Founded



345 Park Avenue,New York, NY 10154

Type of Company


Employees (Worldwide)



Medical Support Services
Hospitals & Patient Services

Company Description

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Contact Data
Trying to get in touch with decision makers at Bristol-Myers Squibb Company? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Head, Corporate & Employee Communications

Chief Financial Officer, Executive Vice President & Director

Executive Vice President, General Counsel

Executive Vice President & Chief Commercial Officer

Chief Information Officer & Executive Vice President

Chief Scientific Officer & Executive Vice President

Chief Human Resources Officer & Executive Vice President

Chief of Staff to the Chief Executive Officer

Senior Vice President, Principal Accounting Officer & Corporate Controller

Board of Directors

Chief Executive Officer at Bristol-Myers Squibb Company

Reddit, Inc.

Co-Director of the Wills Vision Research Center at Thomas Jefferson University

Former President & Chief Financial Officer at Bausch + Lomb, Inc.

Venture Partner at ARCH Venture Partners

Former Acting Chief Executive Officer at Eli Lilly & Company

Former Chief Executive Officer & Director at OraPharma, Inc.

Executive Officer, Director at Adolor Corp.

Former President & Chief Executive Officer at Vertex Pharmaceuticals, Inc.

Former President at Capital Guardian Trust Co.

Paths to Bristol-Myers Squibb Company
Potential Connections via
Relationship Science
Bristol-Myers Squibb Company
Owners & Shareholders
Details Hidden

JPMIM utilizes different methods of analysis that are tailored for each of the investment strategies they offer their clients. They use different methods of analysis and investment strategies in formulating investment advice or managing assets. The firm employs global fundamental research, quantitative valuation tools and bottom-up portfolio construction methods. Research analysts evaluate the US market by sector, while globally-based portfolio managers and analysts cover the international capital markets. JPMIM integrates the skills of their research analysts with those of experienced portfolio managers and economists to leverage information and choose the most fundamentally attractive investments.

Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. Their portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. WMC supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Details Hidden

BHI-IM employs the value investing principles of Benjamin Graham. Their investment approach focuses on buying shares of companies as a long-term investment. The firm seeks to invest in businesses that are easy to understand and have high ROE, exceptional management teams and limited debt. Rather than a diversified stock portfolio, BHI-IM invests in a small number of trusted investments that are overweighed in order to leverage the expected returns. The firm owns stock in a diverse group of over 50 public and private companies in wide range of industries including, but not limited to, manufacturing, retail, energy and finance. Investments are typically financed using the float from Berkshire Hathaway, Inc.'s insurance operations. Securities are sold when the firm no longer feels comfortable with the fundamentals of a company.

Recent Transactions
Details Hidden

Catalent, Inc. purchases Bristol-Myers Squibb Co. /Anagni Manufacturing Facility from Bristol-Myers Squibb Company

Details Hidden

Bristol-Myers Squibb Company purchases Celgene Corp.

Details Hidden

Taisho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd. purchase UPSA SAS from Bristol-Myers Squibb Company

Transaction Advisors
Legal Advisor

Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.


Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Amylin Pharmaceuticals, Inc.

Advisors & Consultants
Legal Advisor

Partner at Sidley Austin LLP


Limited Partner at Lead Edge Capital Management LLC

Legal Advisor

Shareholder at Greenberg Traurig LLP


Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Enterprise Value / Sales
TEVNet Income
Debt TEV
Total Debt
Enterprise Value EBITDAOperating
Total Equity
Three Year Compounded Annual Growth Rate Of Revenue
Non-Profit Donations & Grants
$500 +
$10K - $25K
Non-Profit Donations & Grants Received
Political Donations
Details Hidden

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Details Hidden

Ikena Oncology, Inc. develops metabolic enzymes based immunotherapy for oncology applications. The company was founded by George Georgiou in March 2016 an is headquartered in Austin, TX.

Details Hidden

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

Details Hidden

Managing Director at Lehman Brothers Europe Ltd.

Details Hidden

Founder at The Cross Trust

Details Hidden

Co-Founder at Starboard Value LP

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust. It engages in the ownership, operation, development, and redevelopment of life science and technology properties. The firm also provides a space for lease to the life science and technology industries, which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

TSR, Inc. Auto Parts & Tires | Hauppauge, NY

TSR, Inc. engages in the provision of contract computer programming and staffing services. It supports its clients with technical computer personnel to supplement their in-house information technology capabilities. The company was founded in 1969 and is headquartered in Hauppauge, NY.

Portola Pharmaceuticals, Inc. Pension Funds & Sovereign Wealth | South San Francisco, CA

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Awards & Honors
Rank #168
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #168
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bristol-Myers Squibb Company. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bristol-Myers Squibb Company's profile does not indicate a business or promotional relationship of any kind between RelSci and Bristol-Myers Squibb Company.